Get the Stockscreener App
16.57
1.58%
-0.24
Summit Therapeutics Inc stock is traded at $16.57, with a volume of 626.20K.
It is down -1.58% in the last 24 hours and down -21.18% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$16.81
Open:
$16.8
24h Volume:
626.20K
Relative Volume:
0.16
Market Cap:
$12.51B
Revenue:
$220.00K
Net Income/Loss:
$-746.08M
P/E Ratio:
-16.45
EPS:
-1.0074
Net Cash Flow:
$-211.81M
1W Performance:
-12.13%
1M Performance:
-21.18%
6M Performance:
-31.09%
1Y Performance:
-17.27%
1-Day Range:
$16.54
$17.02
1-Week Range:
$16.45
$18.90
52-Week Range:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
305-203-2034
Address
601 BRICKELL KEY DRIVE, MIAMI
Compare SMMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
16.56 | 12.51B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
ARGX
Argen X Se Adr
|
919.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
201.02 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.67 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
355.12 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.02 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Barclays | Underweight |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Aug-19-25 | Initiated | Piper Sandler | Neutral |
| Jul-01-25 | Initiated | UBS | Buy |
| Jun-11-25 | Initiated | Leerink Partners | Underperform |
| Mar-26-25 | Upgrade | Citigroup | Neutral → Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-12-25 | Initiated | Evercore ISI | Outperform |
| Feb-28-25 | Initiated | Goldman | Buy |
| Jan-08-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Nov-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-24 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| May-07-24 | Initiated | Citigroup | Buy |
| Mar-26-24 | Initiated | Stifel | Buy |
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying (NASDAQ:SMMT) - Seeking Alpha
Has Summit Therapeutics Inc. found a price floorJuly 2025 Trends & Free Weekly Chart Analysis and Trade Guides - newser.com
Wolfe Research Initiates Coverage of Summit Therapeutics (SMMT) with Peer Perform Recommendation - Nasdaq
Summit Therapeutics at Jefferies London: Strategic Progress in Cancer Trials By Investing.com - Investing.com Canada
Wolfe Research Initiates Coverage on SMMT with 'Peer Perform' Ra - GuruFocus
Transcript : Summit Therapeutics Inc. Presents at Jefferies London Healthcare Conference 2025, Nov-18-2025 03 - MarketScreener
What institutional flow reveals about Summit Therapeutics Inc.GDP Growth & Real-Time Buy Zone Alerts - newser.com
What MACD and RSI say about Summit Therapeutics Inc.July 2025 Closing Moves & Advanced Swing Trade Entry Alerts - newser.com
Is Summit Therapeutics Inc. building a consolidation baseWeekly Investment Recap & Verified Stock Trade Ideas - newser.com
News impact scoring models applied to Summit Therapeutics Inc.Options Play & Technical Pattern Alert System - newser.com
Is Summit Therapeutics Inc. showing signs of accumulationJuly 2025 Pullbacks & High Yield Stock Recommendations - newser.com
Should you hold or exit Summit Therapeutics Inc. nowJuly 2025 Highlights & Free Verified High Yield Trade Plans - newser.com
Is Summit Therapeutics Inc. stock a safe haven assetForecast Cut & Short-Term High Return Ideas - Fundação Cultural do Pará
Analyzing Summit Therapeutics Inc. with risk reward ratio chartsWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Can Summit Therapeutics Inc. hit a new high this monthInsider Selling & Weekly Return Optimization Plans - newser.com
Summit Therapeutics (SMMT) Reports Positive Results from the Phase III HARMONi Trial - Yahoo Finance
Responsive Playbooks and the SMMT Inflection - news.stocktradersdaily.com
Summit and Akeso ivonescimab’s shows significant OS benefit - The Pharma Letter
Clear Street Remains a Buy on Summit Therapeutics (SMMT) - The Globe and Mail
Insiders Are Buying These 3 Stocks Hand Over Fist - AOL.com
Summit Therapeutics Reports Positive Phase III Trial Results - MSN
Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China - Placera.se
Summit Therapeutics Says Ivonescimab, Chemotherapy Combination Shows Benefit in Treating Lung Cancer - MarketScreener
Summit Therapeutics Inc Reports Positive Phase III Trial Results - TradingView
[8-K] Summit Therapeutics Inc. Reports Material Event | SMMT SEC FilingForm 8-K - Stock Titan
Summit (NASDAQ: SMMT): ivonescimab combo OS 16.8 vs 14.1 mo in EGFRm NSCLC - Stock Titan
Will Summit Therapeutics Inc. stock outperform growth indexesSwing Trade & Verified Short-Term Trading Plans - fcp.pa.gov.br
Applying sector rotation models to Summit Therapeutics Inc.Weekly Profit Analysis & AI Powered Market Entry Strategies - newser.com
Transforming Lung Cancer Care Through Targeted Science and Patient-First InnovationSummit Therapeutics - Oncodaily
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.10%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):